Thomas P Miller

  • 19295 Citations
  • 58 h-Index
1978 …2016

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Letter
2016

Phase I study of single-agent CC-292, a highly selective bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

Brown, J. R., Harb, W. A., Hill, B. T., Gabrilove, J., Sharman, J. P., Schreeder, M. T., Barr, P. M., Foran, J. M., Miller, T. P., Burger, J. A., Kelly, K. R., Mahadevan, D., Ma, S., Li, Y., Pierce, D. W., Barnett, E., Marine, J., Miranda, M., Azaryan, A., Yu, X. & 3 others, Nava-Parada, P., Mei, J. & Kipps, T. J., Jan 1 2016, In : Haematologica. 101, 7, p. e295-e298

Research output: Contribution to journalLetter

26 Scopus citations
2012

Reply to "Fc gamma receptor 3a genotype in follicular lymphoma: The end of the story?" Haematologica. 2012;97(11): e45

Persky, D. O., Dornan, D., Goldman, B. H., Braziel, R. M., Fisher, R. I., LeBlanc, M., Maloney, D. G., Press, O. W., Miller, T. P. & Rimsza, L. M., Nov 1 2012, In : Haematologica. 97, 11, p. e46

Research output: Contribution to journalLetter

2005

In Reply [2]

Miller, T. P. & Grogan, T. M., Dec 1 2005, In : Journal of Clinical Oncology. 23, 35, p. 9030-9031 2 p.

Research output: Contribution to journalLetter

2000

Interferon does not prolong progression-free survival after ProMACE-MOPP [5] (multiple letters)

Cabanillas, F., Fisher, R. I., Leblanc, M. & Miller, T., Sep 15 2000, In : Journal of Clinical Oncology. 18, 18, 1 p.

Research output: Contribution to journalLetter

1998

Treatment of intermediate-grade and high-grade non-Hodgkin's lymphoma [1] (multiple letters)

Wirth, A., Prince, H. M., Wolf, M., Machida, U., Kami, M., Hirai, H., Mounier, N., Gisselbrecht, C., Lepage, E., Kosmas, C., Malamos, N. A., Antonopoulos, M. J., Decaudin, D., Miller, T., LeBlanc, M. & Fisher, R. I., Nov 12 1998, In : New England Journal of Medicine. 339, 20, p. 1475-1477 3 p.

Research output: Contribution to journalLetter

1 Scopus citations
1991

A clinical phase II study of ProMACE-CytaBOM [1]

Dahlberg, S., Miller, T. P. & Fisher, R. I., Jan 1 1991, In : Journal of Clinical Oncology. 9, 5, 1 p.

Research output: Contribution to journalLetter

1988

The reply

Grogan, T. M., Lippman, S. & Miller, T. P., Jan 1988, In : The American journal of medicine. 84, 1, p. 182-183 2 p.

Research output: Contribution to journalLetter